Anti-FGFR2 antibodies

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8481688
APP PUB NO 20110305687A1
SERIAL NO

13105521

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
AVEO PHARMACEUTICALS INC30 WINTER STREET BOSTON MA 02108

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bai, Ailin Newton, US 33 312
Chen, Ting Acton, US 211 4505
Gyuris, Jeno Lincoln, US 63 604
Meetze, Kristan Lexington, US 22 178
Weiler, Solly Newton, US 17 213
Weng, Zhigang Brookline, US 15 145
Winston,, Jr William M Marlborough, US 32 270

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 9, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00